Cidara Therapeutics Total Revenue

The latest total revenue for CDTX is $0 as of September 2025. That compares with $26M in the prior-year period — down 100.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Cidara Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CDTX's total revenue moved from $26M to $0 — a 100.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cidara Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, CDTX currently prints $0 for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Cidara Therapeutics's growth, margins, and balance sheet.

A total revenue figure of $0 for CDTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting CDTX's total revenue ($0), review year-over-year change from $26M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.